3‐year‐survival · adult patients after liver transplantation.
It is very uncertain whether parenteral nutrition with protein, fat, carbohydrates and… changes 3‐year‐survival compared with 5% dextrose and normal saline (very low certainty).
1 finding from 1 review
1‐year‐survival · adult patients after liver transplantation.
It is very uncertain whether parenteral nutrition with alanyl‐glutamine, protein, fat,… changes 1‐year‐survival compared with 5% dextrose and normal saline (very low certainty).
1 finding from 1 review
3‐year‐survival · adult patients after liver transplantation.
It is very uncertain whether parenteral nutrition with alanyl‐glutamine, protein, fat,… changes 3‐year‐survival compared with 5% dextrose and normal saline (very low certainty).
1 finding from 1 review
Intervention not reported
Amino acids(2 trials; 98 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Amino acids plus vitamin C(1 trial; 191 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Amino acids(1 trial; 78 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Amino acids(2 RCT; 152 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether the intervention changes amino acids(2 RCT; 152 participants) (very low certainty).
1 finding from 1 review
OR 0.61 [0.28, 1.28]
Studies not reported
Very low
Intervention not reported
Amino acids + vitamin C(1 RCT; 191 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether the intervention changes amino acids + vitamin C(1 RCT; 191 participants) (very low certainty).
1 finding from 1 review
OR 1.76 [0.62, 5.53]
Studies not reported
Very low
Intervention not reported
Amino acids(1 RCT; 78 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether the intervention changes amino acids(1 RCT; 78 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Amino acids(2 trials; 158 participants) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Hepatocellular carcinoma · people with acute hepatitis C infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cholangiocarcinoma · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes cholangiocarcinoma compared with placebo (very low certainty).
1 finding from 1 review
The urinary amino telopeptides of collagen I (NTx) (nmol bone collagen equivalents /mmol creatinine) · patients with primary biliary cirrhosis.
1 finding from 1 review
The urinary amino telopeptides of collagen I (NTx) (nmol bone collagen equivalents /mmol creatinine) · patients with primary biliary cirrhosis.
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with unresectable hepatocellular carcinoma
Double‐dose adenovirus‐thymidine kinase with ganciclovir… may leads to lower all‐cause mortality compared with liver transplantation (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found